Major changes have been made to the rules related to drug manufacturing and clinical trials in India in 2026. The government makes the entire process faster, transparent, and easier. These changes have come through amendments to the New Drugs and Clinical Trials Rules under the Drugs and Cosmetics Act, 1940.
These new rules are very important for pharmaceutical companies, researchers, and investors. Because now the approval for manufacturing and testing drugs will be available much faster than before. The applicants seeking a CDSCO test license and a drug manufacturing license will be in a positive and happy space. Some new conditions have also been added to maintain compliance.
In this blog, we will understand the main changes of this 2026 update, such as the prior intimation system, shorter approval time, and new compliance rules.
An Overview of the New Drug Manufacturing and Clinical Trial Rules 2026 Amendment
Earlier, according to the 2019 rules, many steps had to be followed to make a new drug or start research. This took a lot of time. Many companies used to get delayed in starting research. So, the process was a little complicated.
A new drug and manufacturing and clinical trial rules 2026 amendment was brought on 20 January 2026. It comes into effect within about 45 days of its publication in the Gazette.
The new drug manufacturing and clinical trial rules of 2026 have introduced a trust-based system. Strict approval is not required in low-risk cases like before. A simple process has been kept. This makes research and development work faster.
Key Changes in the 2026 Rules
These new rules of 2026 made some important changes. These have made the entire process easier and faster.
- The prior intimation system has been introduced, where work can be started in many cases by simply informing instead of prior approval.
- The approval timeline has been reduced from 90 days to 45 days.
- The process of obtaining permission for drug manufacturing has been made much easier.
- New rules have been introduced for the manufacture of unapproved APIs.
- Compliance and record-keeping rules have been tightened.
Now, we will understand each change in detail.
Introduction of Prior Intimation System
The most important change in the new drug manufacturing and clinical trial rules 2026 amendment is the introduction of the “prior intimation” system. There is no need to take prior permission. You just need to inform the authorities, and work can start.
Earlier, permission had to be obtained from the Central Licensing Authority (CLA) before manufacturing any new or investigational drug. This process used to take a lot of time.
Now, according to the new rule, manufacturers can give prior intimation online by submitting Form CT-10. They can start production only after receiving acknowledgement from the CLA.
There are some major advantages of this change:
- It takes much less time
- Research and trials can be started quickly
- Unnecessary delays are reduced
However, this facility is not applicable in all cases. Some high-risk drugs still cannot be manufactured without full approval as before.
These types of drugs are:
- Cytotoxic drugs
- Narcotic and psychotropic substances
- Sex hormone drugs
- Beta-lactam drugs
- Biologics containing live microorganisms
This category of drugs still requires full approval. This ensures patient safety.
Talk To Expert
Ensure compliance with new 2026 rules—consult us today.
(4.8)
Reduction in Approval Timelines
The approval timeline has also been reduced. Where it used to take about 90 working days earlier, now it has been reduced to 45 working days. This is a big relief for companies.
Key benefits of this change are:
- The process of making drugs can be started much faster
- Research and development time is reduced
- Companies can plan their products better
- New ideas and innovations can be implemented faster
These 2026 changes have had a big impact on the pharma sector. But the application needs to be completed correctly to get quick approval.
Rules for Manufacturing New Drugs
According to the new rules, manufacturers will have to comply with certain conditions when they manufacture new or investigational drugs. These conditions are mainly designed to maintain safety and quality.
First, such drugs can only be used for testing, clinical trials, or research. They cannot be sold in the market in any way. The production volume must be limited and must be produced only in approved places.
The rules are:
- The drug will be used only for research or testing purposes
- No commercial sale can be made
- Limited quantities must be produced
- Only in approved facilities can it be produced
- Good Manufacturing Practices (GMP) must be followed
These rules ensure safety while manufacturing the drug and the patient’s health.
Read more – How to Get a Retail Drug License for your Pharmacy in 2026?
New Provisions for Unapproved APIs
An API is the key component of a drug. So, it is the part that directly affects the disease. The new rules of 2026 have brought some flexibility in the manufacture of unapproved APIs so that research and development are easier.
Now, manufacturers can manufacture APIs with prior intimation. It is a much faster process than before.
In this case, two important forms are:
- Form CT-12 → for formulation manufacturers
- Form CT-13 → for API manufacturers
Companies are getting approvals faster. Research work is starting early. The overall process has become smooth.
Suspension and Cancellation Rules
The new rules have given stronger powers to the regulatory authorities so that they can act quickly. If a manufacturer does not comply with the rules, their permission can be canceled or suspended.
Such situations can occur:
- Non-compliance
- Safety issues
- Breach of conditions
However, this process is not at all one-sided. The manufacturer is allowed to express his views first.
The process is:
- Opportunity to give an explanation
- Right to appeal if necessary
These rules show that the government is providing an easy process and maintaining strict surveillance.
Record-Keeping and Documentation
The new rules place a lot of emphasis on record-keeping and documentation. Maintaining proper information is crucial for tracking any future problems. Each manufacturer will have to keep detailed information about their production and usage.
The information that is important to keep:
- How much medicine has been manufactured
- How much has been used in clinical trials or testing
- How much has been supplied for other approved purposes
- How much has been wasted or destroyed
It also needs to keep a record of unused, expired, or poor-quality items. These rules increase transparency and accountability.
Updated Labelling Requirements
According to the new rules, the labelling of medicines prepared for research or testing has been clarified. Through this, the correct information about each medicine can be easily known.
The mandatory information included in the label is:
- Name and address of the manufacturer
- Name and address of the person to whom the medicine is being given
- Scientific name or identification of the medicine
- The purpose of the medicine
This rule makes it easy to track each medicine. So, labelling plays a very important role in maintaining drug safety.
Impact of the 2026 Amendments
These changes in 2026 have a huge impact on the pharmaceutical sector. Different stakeholders are also benefiting from this.
For pharma companies:
- Approval is getting faster
- New drugs are being developed faster
For CROs (Contract Research Organizations):
- It has become easier to start clinical trials
- Waiting for approval has reduced
For investors:
- The regulatory environment has become clearer
- Investment risk has slightly reduced
Overall, the impact of these changes is-
- Innovation is increasing
- Compliance is becoming tighter
- India is becoming more competitive in the global market
The government is making it easier to do business and also giving equal importance to maintaining safety and quality.
Read more – A Guide to File Drug License Application in India
How Can Corpbiz Help You?
Understanding and following the new 2026 rules can be difficult at times. Here, Corpbiz provides businesses with comprehensive professional support to help them maintain compliance.
How Corpbiz helps:
- Assistance in regulatory approvals and registrations
- Guide to obtaining a drug manufacturing license
- Ensure compliance as per NDCT Rules
- Provide necessary documentation and online filing support
- Provide advice on clinical trials and APIs
Corpbiz’s expert team simplifies the entire process. We help prepare documents correctly and get approval quickly. So, businesses can move forward without a hassle.
Conclusion
There have been several major changes in the new Drug Manufacturing and Clinical Trial rules of 2026. Now the approval process has become much faster than before, but the rules have also become a little stricter.
An attempt has been made to maintain a balance in this new system. Companies should be able to work quickly, while safety should also be maintained. So, the most important thing for businesses is to have a clear idea about these updated rules.
Corpbiz can be a reliable partner. It becomes much easier to comply with these changes, and business growth also accelerates with the right guidance. Therefore, contact us today for easy compliance.
Common Questions About New Drug Manufacturing and Clinical Trial Rules 2026
What are the New Drugs and Clinical Trials Rules, 2026?
These rules are actually some updated guidelines of 2026. These have been brought to make the drug manufacturing and testing process a little easier and faster. Earlier, there was a lot of delay; an attempt has been made to reduce it. This is an updated version of the 2019 rules. Therefore, now the work will be a little faster, and safety will also be maintained.
What is the prior intimation system in drug manufacturing?
Prior intimation means that in many cases, permission is not required in advance. The manufacturer simply informs the authority through Form CT-10. Then, after receiving acknowledgement, they can start working. This is mainly for low-risk drugs. It does not delay the start of research. The process has become much simpler, honestly.
Which drugs are excluded from the prior authorization system?
Prior intimation does not apply to all drugs. Some high-risk drugs still require full approval. For example, cytotoxic drugs, narcotic and psychotropic drugs, sex hormones, beta-lactam drugs, and live biologics. These drugs are a bit sensitive, so they cannot be manufactured directly. Permission has to be obtained in advance. This procedure has been kept to ensure safety.
How have approval timelines changed in 2026?
Earlier, it took about 90 working days to get approval. Now it has been reduced to 45 working days. So, the work is getting a little faster now. Companies can start their projects quickly. But the application has to be submitted properly. Otherwise, it may be delayed again.
Can manufacturers sell drugs produced under these rules?
No, drugs produced under these rules cannot be sold in the market. These are only for testing or clinical trials. Commercial use is not allowed at all. Because they are not yet fully approved. So, it is not safe to reach the public.
What are the requirements for manufacturing unapproved APIs?
Manufacturers have to follow some rules to manufacture unapproved APIs. They must give prior intimation and submit specific forms, such as CT-12 (for formulation) and CT-13 (for API). In addition, production should be for research or testing only. GMP should always be followed, and proper documentation should be kept.
What happens if a company violates these rules?
If a company does not follow the rules, then the authorities can take action. For example, it can cancel or suspend permission, but not suddenly. The company is given a chance to explain it first. They can also appeal if they want. So, it is better to follow the rules.
Why is recordkeeping important under the new rules?
Recordkeeping is very important because it makes the entire process transparent. Manufacturers have to keep all the information about the amount of manufactured, used, or destroyed medicines. It helps to track everything to solve any rising problems. In addition, the regulatory authority can audit these records if they want.
What are the new labeling requirements?
The new rules have asked to make the label a little clearer. Now the manufacturer's name, address, drug info, and use purpose must be written on the label. This makes it easy to track drugs. It can be handled quickly when there's an issue.
How can Corpbiz help with drug manufacturing compliance?
Corpbiz helps businesses maintain drug manufacturing compliance. We support licensing, registration, documentation, and filing. We also provide guidance on working correctly according to the NDCT rules. Our expert team simplifies the entire process so that the company gets approval quickly and does not face any legal problems.
Read more – How to obtain a Drug License for Wholesale Business in India?
Talk To Expert
Ensure compliance with new 2026 rules—consult us today.
(4.8)
